31/08/2023
๐๐๐๐ ๐๐ง๐ง๐จ๐ฏ๐๐ญ๐ ๐๐ง๐ง๐จ๐ฎ๐ง๐๐๐ฌ ๐๐ก๐ ๐๐๐ฎ๐ง๐๐ก ๐จ๐ ๐๐ฉ๐ข๐๐๐๐ยฎ, ๐๐ก๐ ๐๐จ๐ฆ๐ฉ๐๐ง๐ฒ'๐ฌ ๐๐๐ฌ๐ญ ๐๐จ๐ซ ๐ญ๐ก๐ ๐๐๐ซ๐ฅ๐ฒ ๐๐๐ญ๐๐๐ญ๐ข๐จ๐ง ๐จ๐ ๐๐ง๐๐จ๐ฆ๐๐ญ๐ซ๐ข๐๐ฅ ๐๐๐ง๐๐๐ซ - ๐๐ฌ ๐๐๐๐ญ๐ฎ๐ซ๐๐ ๐๐ฒ ๐๐ข๐จ๐๐ฉ๐๐๐ญ๐ซ๐ฎ๐ฆ. ๐ธ๐ฌ
INEX Innovate, is pleased to announce the launch of epiHERAยฎ the companyโs early endometrial cancer detection technology, unveiled at the 2023 Singapore International Congress of Obstetrics and Gynaecology (SICOG).
With 1 in 10 women suffering from abnormal bleeding during their lifetime and requiring an invasive specialist biopsy procedure to rule out endometrial cancer. By using the widely accepted PAP smear or HPV sampling procedure instead, epiHERAยฎ holds great potential as an adjunct tool to help clinicians right at the clinic.
At the core of epiHERAยฎ lies an advanced PCR test designed to identify epigenetic alterations in genes linked to the presence of endometrial cancer. This streamlined process concludes within approximately six hours.
Made in Singapore ๐ธ๐ฌ in collaboration with our partner JH CisPoly, INEX Innovate's epiHERAยฎ technology addresses a crucial gap in current diagnostics by promoting equitable access to testing for vulnerable women.
The novel methodology optimizes sample acquisition, significantly decreasing turnaround time from weeks to days. The scalability of molecular PCR testing assures broad accessibility, further amplifying the impact of epiHERAยฎ within the domain of women's health.
In validation studies undertaken, and ongoing, at The Chinese University of Hong Kong (CUHK) epiHERAยฎ has shown promising results. epiHERAยฎ now is available for Research Use Only.
To find out more please read the article below by BioSpectrum Asia
I IGene NIPT Endometrial Cancer
Novel epiHERAยฎ methodology optimizes sample acquisition, significantly reducing turnaround time from weeks to days, enabling equitable access to critical diagnostics
